vernakalant

06/01/2011 - "In pivotal, randomized, phase III trials, intravenous vernakalant 3 mg /kg administered as a 10-minute infusion, followed by a 2 mg/kg 10-minute infusion after 15 minutes if atrial fibrillation persisted, was effective in the rapid termination of recent-onset atrial fibrillation in nonsurgical patients (≥ 3 hours' to ≤ 7 days' duration) and in those with postoperative atrial fibrillation (3-72 hours' duration) following cardiac surgery. "
01/22/2011 - "In pivotal randomized, phase III trials, intravenous vernakalant 3 mg/kg administered as a 10-minute infusion, followed by a 2 mg/kg 10-minute infusion after 15 minutes if atrial fibrillation persisted, was effective in the rapid termination of recent-onset atrial fibrillation in nonsurgical patients (≥3 hours' to ≤7 days' duration) and in those with postoperative atrial fibrillation (3-72 hours' duration) following cardiac surgery. "
01/01/2018 - "Vernakalant is effective for rapid conversion of recent-onset atrial fibrillation into NSR. "
09/01/2017 - "Additional treatment with vernakalant (10 μmol/l) induced a significant reduction of atrial fibrillation (6 of 15 hearts, 63 episodes). "
06/01/2011 - "Intravenous vernakalant is effective for the rapid pharmacological conversion of atrial fibrillation. "

11/01/2008 - "In clinical Phase II and III studies, vernakalant was moderately (approximately 50%) effective in converting AF of short duration (< 7 days), and effective (approximately 70-80%) in converting AF of less than 72 h, but was not effective in converting long duration AF (>7 days) or atrial flutter. "
12/01/2009 - "Vernakalant seems to be effective in terminating recent-onset AF, but is not efficacious in long-lasting AF and atrial flutter. "
06/01/2012 - "This study examined the safety and efficacy of vernakalant in converting atrial flutter (AFL) to sinus rhythm. "
07/01/2012 - "Plasma vernakalant concentration data from 5 phase 2 and 3 clinical trials of vernakalant in patients with AF or atrial flutter and a phase 1 study in healthy volunteers were used to construct a population pharmacokinetic model. "
06/01/2012 - "Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial."

01/01/2007 - "The study was being conducted by co-development partner Astellas Pharma and measured the safety and efficacy of intravenous vernakalant in recent onset atrial arrhythmia patients. "
04/09/2022 - "(4) Conclusions: The results demonstrated that vernakalant can prolong APD and reduce arrhythmia-like events in SQTS1-hiPSC-CMs and may be a candidate drug for treating arrhythmias in SQTS1-patients."
06/01/2011 - "Increases in QRS or QT intervals were transient, and there was no increased incidence of ventricular arrhythmia observed with vernakalant compared with placebo. "
01/22/2011 - "Increases in QRS or QT intervals were transient, and there was no increased incidence of ventricular arrhythmia observed with vernakalant compared with placebo. "
11/01/2010 - "The first infusion of placebo or vernakalant (3 mg/kg) was given for 10 minutes followed by a second infusion of placebo or vernakalant (2 mg/kg) 15 minutes later if the arrhythmia had not terminated. "

01/01/2014 - "Vernakalant converts new-onset AF to sinus rhythm in approximately 50% of patients, but data on its efficacy and safety in critically ill patients are lacking. "
01/01/2014 - "This study investigates the suitability, safety, and efficacy of vernakalant in critically ill patients with new onset atrial fibrillation (AF) after cardiac surgery. "
01/01/2014 - "Suitability, efficacy, and safety of vernakalant for new onset atrial fibrillation in critically ill patients."
10/01/2011 - "The novel Kv1.5 channel blocker vernakalant for successful treatment of new-onset atrial fibrillation in a critically ill abdominal surgical patient."

01/01/2020 - "Vernakalant is effective in converting recent-onset AF to sinus rhythm rapidly, while significantly more bradycardia events are related to vernakalant in our meta-analysis."
01/01/2020 - "Furthermore, vernakalant was associated with a higher risk of bradycardia in comparison with comparator (6.3% vs. 1.1%, RR 4.04, 95% CI 1.67-9.75, P = 0.002). "
05/01/2012 - "The main adverse effects of vernakalant are cardiac arrhythmias (ventricular arrhythmia, torsades de pointes, bradycardia) and severe hypotension. "